TY - JOUR
T1 - The effects of melatonin supplementation on blood pressure in patients with metabolic disorders
T2 - a systematic review and meta-analysis of randomized controlled trials
AU - Akbari, Maryam
AU - Ostadmohammadi, Vahidreza
AU - Mirhosseini, Naghmeh
AU - Lankarani, Kamran B.
AU - Tabrizi, Reza
AU - Keshtkaran, Zahra
AU - Reiter, Russel J.
AU - Asemi, Zatollah
N1 - Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - The current systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the potential effect of melatonin supplementation on blood pressure in patients with metabolic disorders. The following databases were searched until June 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Two reviewers independently assessed the eligibility of retrieved studies, extracted data from included trials, and evaluated the risk of bias of included studies. Statistical heterogeneity was tested using Cochran’s Q test and I-square (I 2 ) statistic. Data were pooled using random-effect models and standardized mean difference (SMD) was considered as the effect size. Eight RCTs, out of 743 potential citations, were eligible to be included in the current meta-analysis. The pooled findings indicated a significant reduction in systolic (SBP) (SMD = −0.87; 95% CI, −1.36, −0.38; P = 0.001; I 2 : 84.3) and diastolic blood pressure (DBP) (SMD = −0.85; 95% CI, −1.20, −0.51; P = 0.001; I 2 : 68.7) following melatonin supplementation in individuals with metabolic disorders. In summary, the current meta-analysis demonstrated that melatonin supplementation significantly decreased SBP and DBP in patients with metabolic disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention periods to confirm our findings.
AB - The current systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the potential effect of melatonin supplementation on blood pressure in patients with metabolic disorders. The following databases were searched until June 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Two reviewers independently assessed the eligibility of retrieved studies, extracted data from included trials, and evaluated the risk of bias of included studies. Statistical heterogeneity was tested using Cochran’s Q test and I-square (I 2 ) statistic. Data were pooled using random-effect models and standardized mean difference (SMD) was considered as the effect size. Eight RCTs, out of 743 potential citations, were eligible to be included in the current meta-analysis. The pooled findings indicated a significant reduction in systolic (SBP) (SMD = −0.87; 95% CI, −1.36, −0.38; P = 0.001; I 2 : 84.3) and diastolic blood pressure (DBP) (SMD = −0.85; 95% CI, −1.20, −0.51; P = 0.001; I 2 : 68.7) following melatonin supplementation in individuals with metabolic disorders. In summary, the current meta-analysis demonstrated that melatonin supplementation significantly decreased SBP and DBP in patients with metabolic disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention periods to confirm our findings.
UR - http://www.scopus.com/inward/record.url?scp=85060155494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060155494&partnerID=8YFLogxK
U2 - 10.1038/s41371-019-0166-2
DO - 10.1038/s41371-019-0166-2
M3 - Review article
C2 - 30647466
AN - SCOPUS:85060155494
SN - 0950-9240
VL - 33
SP - 202
EP - 209
JO - Journal of Human Hypertension
JF - Journal of Human Hypertension
IS - 3
ER -